Exploring 9-benzyl purines as inhibitors of glutamate racemase (MurI) in Gram-positive bacteria

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 15, 2008, Pages 4368-4372

  Geng, Bolin ^a   Breault, Gloria ^a   Comita Prevoir, Janelle ^a   Petrichko, Randy ^a   Eyermann, Charles ^a   Lundqvist, Tomas ^b   Doig, Peter ^a   Gorseth, Elise ^a   Noonan, Brian ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Benzyl purine; Glutamate racemase; MurI inhibitor

Indexed keywords

BACTERIAL ENZYME; GLUTAMATE RACEMASE; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SCREENING; ENZYME INHIBITION; GRAM POSITIVE BACTERIUM; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

AMINO ACID ISOMERASES; ANTI-BACTERIAL AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIA; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PURINES; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

BACTERIA (MICROORGANISMS); POSIBACTERIA;

EID: 47949123936     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.06.068     Document Type: Article

References (24)

1. Bush K. Clin. Microbiol. Infect. 10 (2004) 10
2. Payne D.J., Gwynnn M.N., Holmes D.J., and Rosenberg M. Methods Mol. Biol. 266 (2004) 231
3. Doublet P., van Heijenoort J., and Mengin-Lecreulx D. J. Bacteriol. 174 (1992) 5772
4. Glavas S., and Tanner M.E. Biochemistry 40 (2001) 6199
5. Doublet P., van Heijenoort J., and Mengin-Lecreulx D. Biochemistry 33 (1994) 5285
6. Van Heijenoort J. Nat. Prod. Rep. 18 (2001) 503
7. For competitive inhibitors:. Glavas S., and Tanner M.E. Bioorg. Med. Chem. Lett 7 (1997) 2265
8. Tanner M.E., and Miao S. Tetrahedron Lett. 35 (1994) 4073
9. De Dios A., Priesto L., Martin J.A., Rubio A., Ezquerra J., Tebbe M., Lopez de Uralde B., Martin J., Sanchez A., LeTourneau D., McGee J.E., Boylan C., Parr Jr. T.R., and Smith M.C. J. Med. Chem. 45 (2002) 4559
10. For peptide ligand, see:. Kim W.C., Rhee H.I., Park B.K., Suk K.H., and Cha S.H. J. Biomol. Screen. 5 (2000) 435
11. For investigation of structural and regulatory diversity of glutamate racemases, see:. Lundqvist T., Fisher S.L., Kern G., Folmer R.H.A., Xue Y., Newton D.T., Keating T.A., Alm R., and de Jonge B.L.M. Nature 447 (2007) 817
12. Laxer A., Major D.T., Gottlieb H.E., and Fischer B.. J. Org. Chem. 66 (2001) 5463
13. Temple, D. L. Jr.; US patent 4286093, 1981.
14. Benedich A., Tinker J.F., and Brown G.B. J. Am. Chem. Soc. 70 (1948) 3109
15. Komatsu H., and Araki T. Nucleosides, Nucleotides and Nucleic Acids 24 (2005) 1127
16. Kurimoto, A.; Ogita, H. JP2005089334 A, Jpn. Kokai Tokkyo Koho, 2005.
17. Kikugawa K., Suehiro H., and Aoki A. Chem. Pharm. Bull. 25 (1977) 1811
18. Kelley J.L., and Schaeffer H.J. J. Heterocycl. Chem. 23 (1986) 271
19. Roblin Jr. R.O., Lampen J.O., English J.P., Cole Q.P., and Vaughan Jr. J.R. J. Am. Chem. Soc. 67 (1945) 290
20. Kurimoto A., Ogino T., Ichii S., Isobe Y., Tobe M., Ogita H., Takaku H., Sajiki H., Hirota K., and Kawakami H. Bioorg. Med. Chem. 12 (2004) 1091
21. 6) δ: 1.00 (t, 3H); 1.48 (m, 2H); 1.72 (m, 2H); 2.60 (m, 4H); 3.64 (m, 6H); 4.27 (t, 2H); 5.43 (s, 2H); 7.21 (t, 2H); 7.54 (m, 1H); 7.64 (br s, 1H); 8.05 (s, 1H).
22. For hydrophobic collaps, see:. Rich D.H. Perspect. Med. Chem. (1993) 15
23. For a recent review on challenges of target-based antibacterial discovery, see:. Payne D.J., Gwynn M.N., Holmes D.J., and Pompliano D.L. Nat. Rev. Drug Discov. 6 (2007) 29
24. AutoDep EBI-36519 PDB ID code 2vvt for the coordinate entry.